February 19, 2026

Advanced Crohn’s Therapies Show Similar Safety

Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.

Conexiant

February 19, 2026

BP Targets Across CKM Stages

Investigators assess stage-specific outcomes, safety, and net benefit of intensive blood pressure control in cardiovascular-kidney-metabolic syndrome.

Conexiant

February 18, 2026

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Conexiant

February 17, 2026

CKD Markers Linked to Cognitive Risk

In adults with chronic kidney disease, higher proteinuria and lower estimated glomerular filtration rate are associated with increased risk of incident cognitive impairment.

Conexiant

February 12, 2026

FDA Approves HRT Label Changes

The agency cited updated evidence in revising hormone therapy safety language.

Conexiant

February 10, 2026

When Obesity Meets Infection Risk

Researchers analyze data from Finnish cohorts and the UK Biobank to examine how body mass index relates to severe infections and their global burden.

Conexiant

February 09, 2026

Short TTP Linked to Infective Endocarditis Risk

While shorter time to blood culture positivity was linked with infective endocarditis, it was not associated with mortality or sepsis in Streptococcus agalactiae bacteremia.

Conexiant

February 04, 2026

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.

KFF Health News

February 02, 2026

Rethinking Prehabilitation Before Surgery

Researchers compare personalized versus standard prehabilitation and examine functional, immune, and postoperative outcomes before major elective surgery.

Conexiant